Opinion|Videos|December 17, 2024
Key Insights on the Use of Inhaled Treprostinil in Treating CTD-PAH
Author(s)Steven D. Nathan, MD
Key Takeaways
- Development of therapies that halt or reverse IPF and PAH progression is a significant unmet need.
- Improved diagnostic tools are essential for earlier detection and intervention in IPF and PAH.
Steven Nathan, MD, discusses how the study on inhaled treprostinil for CTD-PAH demonstrates its comparable efficacy to intravenous and subcutaneous forms, with a better safety profile, which could lead to improved patient adherence and management of CTD-PAH.
Advertisement
Episodes in this series
- Briefly describe the abstract “Inhaled Treprostinil for the Treatment of Connective Tissue-Associated Pulmonary Arterial Hypertension.”
- What was the objective of this study?
- How was this study designed/what methodology was used?
- What results were presented?
- What are your key takeaways from this study, and what are the clinical implications in utilizing inhaled treprostinil compared with intravenous or subcutaneous treprostinil for connective tissue disease-associated PAH?
Advertisement
Related to this article
Ultimately, causality could not be established due to lack of data on disease severity and socioeconomic status, among others.
GRADE meta-analysis: hepatitis A vaccine blocks 96% in pre-exposure vaccination; outbreak response uses millions of doses, but post-exposure prophylaxis evidence is weak.
Alcohol abuse was the strongest post-trauma psychiatric predictor of cardiovascular events, with mood disorders more prominent among women.
Individuals with or at risk for arrhythmogenic cardiomyopathy had no added risk of ventricular arrhythmia from strength training, unlike endurance exercise.
A systematic review finds people with narcolepsy and idiopathic hypersomnia often stay employed but face work impairment and limited workplace support.
Laura Fabbri, MD, discusses bridging idiopathic pulmonary fibrosis (IPF) and oncology research and putting patients at the center of trial design.
Finerenone is the first new FDA-approved treatment in more than 30 years for adults with CKD associated with type 1 diabetes.
Karolinska Institutet reports ROR1 inhibitor KAN571C wipes out double‑resistant MCL after ibrutinib/venetoclax, spotlighting a promising target.
Advertisement
Advertisement